title: Experimental evidence of the potential use of erythropoietin by intranasal administration as a neuroprotective agent in cerebral hypoxia.
abstract: Stroke is a major human health problem without efficient available therapeutics. Ischemic brain injury can induce cell death as well as upregulation of endogenous adaptive mechanisms depending on the severity and duration of hypoxia, and the activity of transcription factors, such as hypoxia inducible factor 1-α (HIF-1α). HIF-1α induces gene expression as multidrug resistance (MDR-1) gene associated with drug-refractory phenotype, as well as erythropoietin (Epo) and erythropoietin receptor (Epo-R) associated with O(2) supply. The spontaneous stimulation of the Epo/Epo-R system is not enough for brain protection. Therefore, administration of exogenous recombinant human Epo (rHu-Epo) was suggested as an alternative therapy in stroke. In several experimental models of brain hypoxia, Epo and Epo variants, including rHu-Epo, showed neuroprotective effects. Intranasal administration of these Epo-compounds can reach the central nervous system and protect the brain against ischemia, avoiding hematopoietic effects. However, it has been reported that high expression of Epo-R in neurons must be available to be activated by Epo. According to these considerations, intranasal delivery of rHu-Epo could be an interesting approach in the treatment of cerebral hypoxias avoiding both (i) adverse peripheral effects of treatment with Epo in stroke, and (ii) the pharmacoresistant phenotype depending on MDR-1 expression.
authors.affiliation: Instituto de Biología Celular y Neurociencias, UBA-CONICET, Buenos Aires, Argentina.
authors.forename: Amalia
authors.initials: A
authors.lastname: Merelli
authors.forename: Laura
authors.initials: L
authors.lastname: Caltana
authors.forename: Alberto
authors.initials: A
authors.lastname: Lazarowski
authors.forename: Alicia
authors.initials: A
authors.lastname: Brusco
mesh_terms: D000281:Administration, Intranasal; D000818:Animals; D004921:Erythropoietin / Q000008:administration & dosage*; D006801:Humans; D002534:Hypoxia, Brain / Q000188:drug therapy*; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000502:physiology; D018696:Neuroprotective Agents / Q000008:administration & dosage*; D017467:Receptors, Erythropoietin / Q000032:analysis; D011994:Recombinant Proteins / Q000008:administration & dosage
chemical_list: D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D018696:Neuroprotective Agents; D017467:Receptors, Erythropoietin; D011994:Recombinant Proteins; D004921:Erythropoietin